ProMIS Neurosciences (PMN) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 24.5% versus a loss of 35.8%. ProMIS Neurosciences is the larger company by market cap ($82.1 million vs $78.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMN | PTHS |
|---|---|---|
| Share price | $9.15 | $20.50 |
| Market cap | $82.05M | $78.48M |
| 1-day change | +0.33% | -2.33% |
| YTD return | +33.97% | -33.87% |
| 1-year return | -35.79% | -24.47% |
| 5-year return | -95.93% | — |
| EPS (TTM) | $-11.65 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.40 | $37.50 |
| 52-week low | $6.27 | $18.19 |
| Distance from 52-week high | -66.61% | -45.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +365.68% | +159.22% |
| Average volume | 84.01K | 60.07K |
| Shares outstanding | 8.97M | 3.83M |
| Employees | 10 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTHS has outperformed PMN by 11.3 percentage points over the past year.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Healthcare · Biotechnology · 10 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Healthcare · Biotechnology · 92 employees
PMN vs PTHS FAQ
Which is bigger, ProMIS Neurosciences or Pelthos Therapeutics?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $82.05M compared with $78.48M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, PMN or PTHS?
PTHS returned -24.47% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are ProMIS Neurosciences and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.